Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology

John Kurhanewicz, Daniel B. Vigneron, Jan Henrik Ardenkjaer-Larsen, James A. Bankson, Kevin Brindle, Charles H. Cunningham, Ferdia A. Gallagher, Kayvan R. Keshari, Andreas Kjaer, Christoffer Laustsen, David A. Mankoff, Matthew E. Merritt, Sarah J. Nelson, John M. Pauly, Philips Lee, Sabrina Ronen, Damian J. Tyler, Sunder S. Rajan, Daniel M. Spielman, Lawrence Wald & 3 others Xiaoliang Zhang, Craig R Malloy, Rahim Rizi

Research output: Contribution to journalReview article

Abstract

This white paper discusses prospects for advancing hyperpolarization technology to better understand cancer metabolism, identify current obstacles to HP (hyperpolarized) 13C magnetic resonance imaging's (MRI's) widespread clinical use, and provide recommendations for overcoming them. Since the publication of the first NIH white paper on hyperpolarized 13C MRI in 2011, preclinical studies involving [1-13C]pyruvate as well a number of other 13C labeled metabolic substrates have demonstrated this technology's capacity to provide unique metabolic information. A dose-ranging study of HP [1-13C]pyruvate in patients with prostate cancer established safety and feasibility of this technique. Additional studies are ongoing in prostate, brain, breast, liver, cervical, and ovarian cancer. Technology for generating and delivering hyperpolarized agents has evolved, and new MR data acquisition sequences and improved MRI hardware have been developed. It will be important to continue investigation and development of existing and new probes in animal models. Improved polarization technology, efficient radiofrequency coils, and reliable pulse sequences are all important objectives to enable exploration of the technology in healthy control subjects and patient populations. It will be critical to determine how HP 13C MRI might fill existing needs in current clinical research and practice, and complement existing metabolic imaging modalities. Financial sponsorship and integration of academia, industry, and government efforts will be important factors in translating the technology for clinical research in oncology. This white paper is intended to provide recommendations with this goal in mind.

LanguageEnglish (US)
Pages1-16
Number of pages16
JournalNeoplasia (United States)
Volume21
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Critical Pathways
Magnetic Resonance Imaging
Technology
Pyruvic Acid
Prostatic Neoplasms
Liver Neoplasms
Research
Brain Neoplasms
Uterine Cervical Neoplasms
Ovarian Neoplasms
Publications
Healthy Volunteers
Industry
Animal Models
Breast Neoplasms
Safety
Population
Neoplasms

ASJC Scopus subject areas

  • Cancer Research

Cite this

Kurhanewicz, J., Vigneron, D. B., Ardenkjaer-Larsen, J. H., Bankson, J. A., Brindle, K., Cunningham, C. H., ... Rizi, R. (2019). Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology. Neoplasia (United States), 21(1), 1-16. https://doi.org/10.1016/j.neo.2018.09.006

Hyperpolarized 13C MRI : Path to Clinical Translation in Oncology. / Kurhanewicz, John; Vigneron, Daniel B.; Ardenkjaer-Larsen, Jan Henrik; Bankson, James A.; Brindle, Kevin; Cunningham, Charles H.; Gallagher, Ferdia A.; Keshari, Kayvan R.; Kjaer, Andreas; Laustsen, Christoffer; Mankoff, David A.; Merritt, Matthew E.; Nelson, Sarah J.; Pauly, John M.; Lee, Philips; Ronen, Sabrina; Tyler, Damian J.; Rajan, Sunder S.; Spielman, Daniel M.; Wald, Lawrence; Zhang, Xiaoliang; Malloy, Craig R; Rizi, Rahim.

In: Neoplasia (United States), Vol. 21, No. 1, 01.01.2019, p. 1-16.

Research output: Contribution to journalReview article

Kurhanewicz, J, Vigneron, DB, Ardenkjaer-Larsen, JH, Bankson, JA, Brindle, K, Cunningham, CH, Gallagher, FA, Keshari, KR, Kjaer, A, Laustsen, C, Mankoff, DA, Merritt, ME, Nelson, SJ, Pauly, JM, Lee, P, Ronen, S, Tyler, DJ, Rajan, SS, Spielman, DM, Wald, L, Zhang, X, Malloy, CR & Rizi, R 2019, 'Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology' Neoplasia (United States), vol. 21, no. 1, pp. 1-16. https://doi.org/10.1016/j.neo.2018.09.006
Kurhanewicz J, Vigneron DB, Ardenkjaer-Larsen JH, Bankson JA, Brindle K, Cunningham CH et al. Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology. Neoplasia (United States). 2019 Jan 1;21(1):1-16. https://doi.org/10.1016/j.neo.2018.09.006
Kurhanewicz, John ; Vigneron, Daniel B. ; Ardenkjaer-Larsen, Jan Henrik ; Bankson, James A. ; Brindle, Kevin ; Cunningham, Charles H. ; Gallagher, Ferdia A. ; Keshari, Kayvan R. ; Kjaer, Andreas ; Laustsen, Christoffer ; Mankoff, David A. ; Merritt, Matthew E. ; Nelson, Sarah J. ; Pauly, John M. ; Lee, Philips ; Ronen, Sabrina ; Tyler, Damian J. ; Rajan, Sunder S. ; Spielman, Daniel M. ; Wald, Lawrence ; Zhang, Xiaoliang ; Malloy, Craig R ; Rizi, Rahim. / Hyperpolarized 13C MRI : Path to Clinical Translation in Oncology. In: Neoplasia (United States). 2019 ; Vol. 21, No. 1. pp. 1-16.
@article{971679f1022845089e35cbe1fc03025b,
title = "Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology",
abstract = "This white paper discusses prospects for advancing hyperpolarization technology to better understand cancer metabolism, identify current obstacles to HP (hyperpolarized) 13C magnetic resonance imaging's (MRI's) widespread clinical use, and provide recommendations for overcoming them. Since the publication of the first NIH white paper on hyperpolarized 13C MRI in 2011, preclinical studies involving [1-13C]pyruvate as well a number of other 13C labeled metabolic substrates have demonstrated this technology's capacity to provide unique metabolic information. A dose-ranging study of HP [1-13C]pyruvate in patients with prostate cancer established safety and feasibility of this technique. Additional studies are ongoing in prostate, brain, breast, liver, cervical, and ovarian cancer. Technology for generating and delivering hyperpolarized agents has evolved, and new MR data acquisition sequences and improved MRI hardware have been developed. It will be important to continue investigation and development of existing and new probes in animal models. Improved polarization technology, efficient radiofrequency coils, and reliable pulse sequences are all important objectives to enable exploration of the technology in healthy control subjects and patient populations. It will be critical to determine how HP 13C MRI might fill existing needs in current clinical research and practice, and complement existing metabolic imaging modalities. Financial sponsorship and integration of academia, industry, and government efforts will be important factors in translating the technology for clinical research in oncology. This white paper is intended to provide recommendations with this goal in mind.",
author = "John Kurhanewicz and Vigneron, {Daniel B.} and Ardenkjaer-Larsen, {Jan Henrik} and Bankson, {James A.} and Kevin Brindle and Cunningham, {Charles H.} and Gallagher, {Ferdia A.} and Keshari, {Kayvan R.} and Andreas Kjaer and Christoffer Laustsen and Mankoff, {David A.} and Merritt, {Matthew E.} and Nelson, {Sarah J.} and Pauly, {John M.} and Philips Lee and Sabrina Ronen and Tyler, {Damian J.} and Rajan, {Sunder S.} and Spielman, {Daniel M.} and Lawrence Wald and Xiaoliang Zhang and Malloy, {Craig R} and Rahim Rizi",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.neo.2018.09.006",
language = "English (US)",
volume = "21",
pages = "1--16",
journal = "Neoplasia (United States)",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Hyperpolarized 13C MRI

T2 - Neoplasia (United States)

AU - Kurhanewicz, John

AU - Vigneron, Daniel B.

AU - Ardenkjaer-Larsen, Jan Henrik

AU - Bankson, James A.

AU - Brindle, Kevin

AU - Cunningham, Charles H.

AU - Gallagher, Ferdia A.

AU - Keshari, Kayvan R.

AU - Kjaer, Andreas

AU - Laustsen, Christoffer

AU - Mankoff, David A.

AU - Merritt, Matthew E.

AU - Nelson, Sarah J.

AU - Pauly, John M.

AU - Lee, Philips

AU - Ronen, Sabrina

AU - Tyler, Damian J.

AU - Rajan, Sunder S.

AU - Spielman, Daniel M.

AU - Wald, Lawrence

AU - Zhang, Xiaoliang

AU - Malloy, Craig R

AU - Rizi, Rahim

PY - 2019/1/1

Y1 - 2019/1/1

N2 - This white paper discusses prospects for advancing hyperpolarization technology to better understand cancer metabolism, identify current obstacles to HP (hyperpolarized) 13C magnetic resonance imaging's (MRI's) widespread clinical use, and provide recommendations for overcoming them. Since the publication of the first NIH white paper on hyperpolarized 13C MRI in 2011, preclinical studies involving [1-13C]pyruvate as well a number of other 13C labeled metabolic substrates have demonstrated this technology's capacity to provide unique metabolic information. A dose-ranging study of HP [1-13C]pyruvate in patients with prostate cancer established safety and feasibility of this technique. Additional studies are ongoing in prostate, brain, breast, liver, cervical, and ovarian cancer. Technology for generating and delivering hyperpolarized agents has evolved, and new MR data acquisition sequences and improved MRI hardware have been developed. It will be important to continue investigation and development of existing and new probes in animal models. Improved polarization technology, efficient radiofrequency coils, and reliable pulse sequences are all important objectives to enable exploration of the technology in healthy control subjects and patient populations. It will be critical to determine how HP 13C MRI might fill existing needs in current clinical research and practice, and complement existing metabolic imaging modalities. Financial sponsorship and integration of academia, industry, and government efforts will be important factors in translating the technology for clinical research in oncology. This white paper is intended to provide recommendations with this goal in mind.

AB - This white paper discusses prospects for advancing hyperpolarization technology to better understand cancer metabolism, identify current obstacles to HP (hyperpolarized) 13C magnetic resonance imaging's (MRI's) widespread clinical use, and provide recommendations for overcoming them. Since the publication of the first NIH white paper on hyperpolarized 13C MRI in 2011, preclinical studies involving [1-13C]pyruvate as well a number of other 13C labeled metabolic substrates have demonstrated this technology's capacity to provide unique metabolic information. A dose-ranging study of HP [1-13C]pyruvate in patients with prostate cancer established safety and feasibility of this technique. Additional studies are ongoing in prostate, brain, breast, liver, cervical, and ovarian cancer. Technology for generating and delivering hyperpolarized agents has evolved, and new MR data acquisition sequences and improved MRI hardware have been developed. It will be important to continue investigation and development of existing and new probes in animal models. Improved polarization technology, efficient radiofrequency coils, and reliable pulse sequences are all important objectives to enable exploration of the technology in healthy control subjects and patient populations. It will be critical to determine how HP 13C MRI might fill existing needs in current clinical research and practice, and complement existing metabolic imaging modalities. Financial sponsorship and integration of academia, industry, and government efforts will be important factors in translating the technology for clinical research in oncology. This white paper is intended to provide recommendations with this goal in mind.

UR - http://www.scopus.com/inward/record.url?scp=85056925374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056925374&partnerID=8YFLogxK

U2 - 10.1016/j.neo.2018.09.006

DO - 10.1016/j.neo.2018.09.006

M3 - Review article

VL - 21

SP - 1

EP - 16

JO - Neoplasia (United States)

JF - Neoplasia (United States)

SN - 1522-8002

IS - 1

ER -